Smart cancer drug on sale in the UK

	Tweet

A new “smart” cancer drug will be available to patients in Britain today which works by deploying two chemical ‘bullets’ that attack specific molecular targets, starving tumours of nutrients and inhibiting the enzyme that signals cells to multiply.

Experts say the two-prong approach may be better than the single approach now offered by the extremely successful drug Glivec.

The drug is will be used to treat patients when other anti-cancer drugs have failed to improve their condition.

The new drug, Sutent, is one of the latest three Glivec-like drugs that are at various stages of development, and cancer specialists believe it will be useful in treating different kinds of tumours.

Since its introduction in 2001, Glivec has transformed the treatment of chronic myeloid leukemia and a rare form of stomach cancer and it may well be useful in treating other cancers too.

Sutent is licensed across the UK to treat metastatic renal cell carcinoma, or advanced kidney cancer, and a rare cancer known as GIST (gastro-intestinal stromal tumour) which affects the stomach.

The groundbreaking new drug was seen in trials in the U.S. to significantly prolong the lives of sufferers with advanced kidney cancer that had not responded to conventional drugs.

Sutent caused tumours to shrink in 40 per cent of patients, and in a further 28 per cent they stabilised.

The treatment however is expensive and costs around $4,500 per month; the National Health Service (NHS) may limit its use to a second treatment only after other drugs fail.

According to experts, it has doubled the time a kidney cancer patient can live without tumour growth and cut the risk of the stomach cancer progressing by 67%.

And early trial results also suggest that Sutent has the potential to be effective against breast, lung and pancreatic cancers.

The drug also improves the patients’ quality of life as it is has a less radical effect on the body than other cancer treatments such as chemotherapy.

Research is now being conducted into whether the drug is effective as a first-line treatment for early stage kidney cancer.

Cancer Research UK has however cautioned against the new treatment being seen as a ‘wonder drug’ and says it is too early for such claims to be justifiable.

RELATED STORIES:
Smoking and hepatitis C up risk of lymphoma   2008 Cancer Incidence and Mortality Report   Many preventable cancers caught at late stage: CDC   Developing world gets tiny share of cancer spend   Moving to U.S. tied to higher cancer risks   New attack on cancer forces cells to grow old & die   Rare Cancer-causing Syndrome Found, for the First Time, in Singapore   Targeting cholesterol may help slow glioblastoma   Combining Two Peptide Inhibitors Might Block Tumor Growth   Discovery Could Lead to Early Cancer Detection, Prevention   U.S. cancer rates continue their decline: report   Study quantifies racial disparities in cancer mortality rates between blacks and whites   Is milk thistle effective in cancer treatment?   Cancer drug Gleevec may damage heart: study   Unlocking the body’s defenses against cancer   Cancer patients, doctors talk little of emotions   Researchers Find Better Method to Help Mothers Cope With Child’s Cancer and Related Stress   New Hope for Cancer Comes Straight from the Heart   Discovery Could Bring New Metastatic Cancer Treatments   How What and How Much We Eat (And Drink) Affects Our Risk of Cancer   Unusual Three-Drug Combo Inhibits Growth of Aggressive Tumors   Not all doctors follow cancer screening guidelines

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]